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Background. Subthreshold psychotic and bipolar experiences are common in major depressive disorder (MDD). How-
ever, it is unknown if effectiveness of psychotherapy is altered in depressed patients who display such features compared
with those without. The current paper aimed to investigate the impact of the co-presence of subclinical psychotic experi-
ences and subclinical bipolar symptoms on the effectiveness of psychological treatment, alone or in combination with
pharmacotherapy.
Method. In a naturalistic study, patients with MDD (n=116) received psychological treatment (cognitive behavioural
therapy or interpersonal psychotherapy) alone or in combination with pharmacotherapy. Depression and functioning
were assessed six times over 2 years. Lifetime psychotic experiences and bipolar symptoms were assessed at the second
time point.
Results. Subclinical psychotic experiences predicted more depression over time (β=0.20, p<0.002), non-remission
[odds ratio (OR) 7.51, p<0.016] and relapse (OR 3.85, p<0.034). Subthreshold bipolar symptoms predicted relapse
(OR 1.16, p<0.037).
Conclusions. In general, subclinical psychotic experiences have a negative impact on the course and outcome of psy-
chotherapy in MDD. Effects of subclinical bipolar experiences were less prominent.
Received 23 October 2012; Revised 20 March 2013; Accepted 21 March 2013
Key words: Bipolar symptoms, cognitive behavioural therapy, interpersonal psychotherapy, major depressive disorder,
psychotic experiences, treatment outcome.
Introduction
Symptoms of psychosis (Hanssen et al. 2003; Varghese
et al. 2011; Kelleher et al. 2012b; Wigman et al. 2012) and
bipolar disorder (Angst et al. 2010; Nusslock & Frank,
2011), at clinical and subclincal levels of expression,
commonly occur in the context of major depressive dis-
order (MDD). This reﬂects overlap between affective
and psychotic disorders in genetic (Craddock et al.
2009) and environmental risk factors (Weiser et al.
2005), as well as in underlying endophenotypes,
for example (neuro)cognitive, social and emotional
dysfunctions (Weiser et al. 2005; Hill et al. 2009;
Simonsen et al. 2011). The overlap in diagnostic con-
structs has important implications for both research
and clinical practice. Theoretically, dimensional clus-
tering of psychopathology challenges the validity
of current diagnostic systems that aim to categorize
essentially continuous psychopathological phenomena
(McGorry & van Os, 2013). Clinically, disregard of sub-
clinical co-expression of psychotic and bipolar symp-
toms may contribute to treatment resistance in MDD,
as suggested by a number of lines of evidence. First,
some but not all studies suggest poorer response to
antidepressants in individuals screening positive for
subclinical bipolar illness features (Sharma et al. 2005;
Smith et al. 2009; Dudek et al. 2010; Perlis et al. 2011).
Second, the presence of subclinical psychotic features
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during an episode of MDD (not fulﬁlling criteria for a
formal diagnosis of psychotic depression) predicts
poor response to multiple antidepressants (Perlis
et al. 2011). To our knowledge, no study has examined
whether the presence of subclinical bipolar and psy-
chotic symptoms in MDD moderates response to
evidence-based psychotherapies like cognitive behav-
ioural therapy (CBT; Beck & Rush, 1979) or interperson-
al psychotherapy (IPT; Klerman et al. 1984).
The aims of the current study were to investigate
the impact of (i) subclinical psychotic experiences and
(ii) subclinical bipolar symptoms on the course and
outcome of MDD when treated with short-term psy-
chotherapy, either alone or in combination with anti-
depressants. More speciﬁcally, outcome variables of
interest cover clinical outcome (severity of depression,
remission, time to remission and relapse of depression)
and functional outcome.
Method
Sample
The study sample consisted of depressed, treatment-
seeking patients presenting at the mood disorders
treatment programme of an out-patient mental health
care centre in Maastricht, The Netherlands. After initial
screening, patients are referred to specialized treatment
programmes for diagnostic work-up and treatment.
During the acute treatment phase, the mood disorders
programme offers most depressed patients CBT or IPT,
either alone or in combination with pharmacotherapy.
The current data came from an observational study de-
signed to examine the effectiveness of evidence-based
treatments for depression in routine clinical practice.
Thus, treatment allocation was based on participants’
preference and not on randomization (Peeters et al.
2013). Peeters et al. (2013) previously showed that psy-
chotherapy interventions, alone or in combination with
pharmacotherapy, are effective in a routine clinical set-
ting. CBT was provided by experienced therapists who
received appropriate training and followed the pro-
cedures outlined in standard texts of cognitive therapy
for depression (Beck & Rush, 1979). IPT, based on the
manual by Klerman et al. (1984), was also provided
by trained and experienced therapists (psychologists,
psychotherapists and psychiatrists).
For the current study, the inclusion criteria were a
primary diagnosis of MDD as assessed with the Struc-
tured Clinical Interview for DSM-IV Axis I (SCID-I;
First et al. 1997) and completion of the Community
Assessment of Psychic Experiences (CAPE) and/or
the Mood Disorder Questionnaire (MDQ). Trained
mental health care professionals conducted the
SCID-I assessments. Exclusion criteria were a primary
diagnosis other than MDD, elevated acute suicide risk
and insufﬁcient command of the Dutch language.
Patients who met Diagnostic and Statistical Manual
of Mental Disorders, 4th Edition (DSM-IV) criteria for
psychotic depression or bipolar disorder were thus
excluded. Co-morbid Axis I diagnoses were allowed.
The study was approved by the Ethics Committee of
Maastricht University. All participants provided writ-
ten informed consent.
Procedure
After the diagnostic work-up, participants were allo-
cated to treatment. Licensed psychologists and psy-
chotherapists, who received appropriate training and
followed the procedures outlined in standard texts,
provided CBT and IPT (Beck & Rush, 1979; Klerman
et al. 1984). Pharmacotherapy typically consisted of
treatment with a serotonin reuptake inhibitor (SSRI),
following national and international guidelines. In
cases of SSRI non-response in the current episode, par-
ticipants were prescribed another SSRI, venlafaxine or
a tricyclic agent augmented with lithium in case of sub-
sequent non-response. Prior to the start of treatment,
baseline measurements were carried out; follow-up
assessments took place after 8, 16, 26, 52 and 104
weeks. A total of 44 (38%) patients received CBT and
40 (34%) patients IPT; 17 (15%) patients received CBT
in combination with pharmacotherapy and 15 (13%)
received IPT in combination with pharmacotherapy.
Instruments
At different time points, different instruments were
used (see Fig. 1). The main outcome variable was the
Beck Depression Inventory, second edition (BDI; Beck
& Steer, 1996). The BDI measures depression severity
using 21 items, with higher scores indicating more
severe depression (range 0–63). Its construct validity
and reliability have consistent support from varied
samples (Beck & Steer, 1996). Using the guidelines of
Jacobson & Truax (1991), response was deﬁned a priori
as a decrease of at least 10 points from baseline BDI
score, whereas remission was conservatively deﬁned
as an absolute BDI score of 10 points or less.
The positive dimension of the CAPE (18 self-report
items), based on the Peters et al. Delusions Inventory
(Peters et al. 1999) and modiﬁed to also include hal-
lucinatory experiences, was used to assess lifetime sub-
clinical positive psychotic experiences (Stefanis et al.
2002; Konings et al. 2006). Each CAPE item rates the
frequency of subclinical psychotic experiences on a
four-point scale; scores can thus range from 18 to 72,
and higher scores indicate more subclinical psychotic
experiences.
The MDQ (Hirschfeld et al. 2000), a screening
instrument for bipolar disorder, was used to assess
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symptoms of subthreshold bipolar (spectrum) dis-
order. The MDQ consists of three sections: part A
addresses 13 yes/no questions addressing occurrence
of (hypo)manic symptoms; part B rates co-occurrence
of multiple symptoms (yes/no) and part C addresses
the level of impact of these symptoms on the individ-
ual’s daily life (none, mild, moderate, severe). The
MDQ also assesses lifetime prevalence of symptoms.
For the purpose of the current study, part A was
used in the analyses. Part A scores can range from 0
to 13, and higher scores indicate more symptoms.
Level of functioning was assessed with the Short
Form-36 (SF-36; Ware & Sherbourne, 1992), which
includes 36 items. The SF-36 rates functional health
and well-being on eight dimensions. The mean score
of the eight dimensions was used as an indicator of a
generic, mental health summary measure, and higher
scores indicate better overall functioning.
Analyses
Analyses were carried out in STATA version 12.0
(StataCorp LP, USA). Comparisons of baseline charac-
teristics and differences between treatment groups
were done with χ2 tests for categorical data and with
analysis of variance or Pearson correlations for
continuous data. Data were analysed in the long for-
mat, modelling the dependent variable assessed at
time points 2, 3, 4, 5 and 6 while correcting for the
baseline value of the dependent variable, taking into
account hierarchical clustering of observations within
persons using the XTREG command.
First, the prevalences of (i) subclinical psychotic
experiences, as assessed with the CAPE, and (ii) sub-
clinical bipolar symptoms, as assessed with the
MDQ, were investigated. Pearson’s correlations were
calculated for BDI, CAPE and MDQ scores in order
to address the degree of association between the
three instruments.
Second, multilevel linear regression was used to pre-
dict BDI scores over time (T2–T6), using (i) CAPE
score, (ii) MDQ score and, when main effects were
found, (iii) interactions between these two respective
measures and time. Third, logistic regression was
used to predict non-remission using (i) CAPE score
and (ii) MDQ score. Fourth, logistic regression was
used to predict relapse (i.e. a BDI score of 10 points
or higher at time point t after having been in remission
at time point t –1) using (i) CAPE score and (ii) MDQ
score. Fifth, time to remission was predicted using
Cox regression with (i) CAPE score and (ii) MDQ
score as predictors. For this analysis, variables of
Baseline SCID, BDI, SF-36
Instruments assessed at this time point:
BDI, SF-36, CAPE, MDQ
BDI, SF-36,
BDI, SF-36,
BDI, SF-36,
BDI, SF-36,
8-week follow-up
16-week follow-up
26-week follow-up
52-week follow-up
104-week follow-up
n=115
n=96
n=90
n=63
n=57
n=116
Start of treatment
Fig. 1. Flowchart of the study design. SCID, Structured Clinical Interview for DSM-IV; BDI, Beck Depression Inventory;
SF-36, Short Form-36; CAPE, Community Assessment of Psychic Experiences; MDQ, Mood Disorder Questionnaire.
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CAPE and MDQ were dichotomized (split around the
mean). All these analyses were controlled for
depression severity (BDI score) at baseline. Finally,
multilevel linear regression was used to predict
T2–T6 level of functioning, expressed as mean SF-36
score and controlling for baseline functioning, using
(i) CAPE score and (ii) MDQ score.
BDI or functioning scores, CAPE score and MDQ
score did not differ between men and women (all
p>0.05). Age was not correlated with BDI score or func-
tioning, nor with CAPE or MDQ score (all p>0.05);
age and sex were therefore not controlled for in the
analyses. There were no differences in BDI baseline
score, CAPE or MDQ score between individuals who
received monotherapy or combined therapy; nor did
these scores differ between individuals who received
CBT or IPT (all p>0.05). Functioning scores did not
differ when comparing monotherapy with combined
therapy. However, comparing these therapy groups
on the type of psychotherapy received revealed that
patients receiving IPT had higher levels of functioning
at baseline compared with patients receiving CBT (p<
0.02; not at other time points). Given these differences,
analyses on functioning were additionally controlled
for receipt of CBT or IPT (hereafter: treatment group).
Since patients reporting subclinical psychotic or
bipolar phenomena may be those that present with
more severe symptoms, expressed as ‘co-morbidity’,
we performed post hoc analyses to see whether patients
with more psychotic experiences (using the dichoto-
mized variable representing the mean split of the
CAPE score) reported more co-morbidity (i.e. the
co-presence of one or more disorders) compared with
patients with fewer psychotic experiences. In addition,
all analyses were repeated controlling for the presence
of co-morbidity.
Results
Sample
The sample consisted of 116 patients who at the second
time point completed the CAPE; MDQ data were avail-
able for 113 patients. Demographic characteristics of
the sample can be found in Table 1. At baseline assess-
ment, eight patients (7%) scored below the clinical cut-
off on the BDI (i.e. a score of 10 or less), increasing to 23
patients (20% of the assessed sample) at the 8-week
follow-up, 35 patients (36%) at the 16-week follow-up,
43 patients (48%) at the 26-week follow-up, 30 patients
(48%) at the 52-week follow-up and 29 patients (51%)
at the 104-week follow-up. Of the total sample, 66
patients (57%) reached remission at least once during
the study. Relapse of depression occurred in 20
patients (17%). More than one disorder (co-morbidity)
was present in 60 patients. Of these 60 patients, 38
(63%) had one additional disorder, 14 (23%) had two
additional disorders, seven (12%) had three additional
disorders and one patient (2%) had four additional
disorders.
Attrition analyses
There were no large or signiﬁcant differences between
individuals who dropped out of the study (i.e. only 59
individuals did not complete the last measurement)
compared with the individuals who completed the
study regarding level of depression, functioning at
baseline, CAPE score and MDQ score. Also, individ-
uals who dropped out were no more likely to receive
monotherapy or combined therapy or to have chosen
IPT or CBT (all p>0.05). Patients who dropped
out showed no sex differences (p>0.05); however,
patients who dropped out at the ﬁnal measurement
were younger than patients who completed the study
[39.6 (S.D. =10.9) v. 47.5 (S.D. =9.4) years, respectively]
(F1,114=17.33, p<0.001). However, since it is unlikely
that young patients for whom subclinical psychosis
would be associated with good outcome were more
likely to drop out of the study compared with older
patients for whom psychosis would be associated
with poor outcome, it is unlikely that this age differ-
ence may have biased the results.
Sublinical psychotic experiences and bipolar
symptoms in the context of depression
Both subclinical psychotic experiences and subclinical
bipolar symptoms were prevalent in depressed
patients and often co-occurred. Of the participants,
96% reported at least one subclinical psychotic experi-
ence; 93% reported at least one bipolar symptom. Also,
89% reported at least one instance of psychosis and
bipolarity together. Fig. 2 shows the distribution of
the co-occurrence of bipolar symptoms and subclinical
psychotic experiences.
Zero-order bivariate correlations of measures of the
BDI, CAPE and MDQ were signiﬁcant at baseline and
at the 8-week follow-up (Table 2). However, when cal-
culating partial correlations, it was shown that at the
8-week follow-up, CAPE and BDI were still signiﬁ-
cantly correlated when controlling for MDQ, whereas
the MDQ was no longer signiﬁcantly correlated with
the BDI when controlling for CAPE. At subsequent
assessments, only CAPE was signiﬁcantly correlated
with BDI score as indicated by both bivariate and par-
tial correlation coefﬁcients.
CAPE and MDQ were also signiﬁcantly correlated at
the 8-week assessment (ρ=0.49, p<0.0001), and after
controlling for depression at that time point (ρ=0.43,
p<0.0001).
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Table 1. Demographic characteristics of participants at baseline
Characteristics
n (%) 116 (100)
Mean age, years (S.D., range) 43.5 (10.8, 20–63)
Sex, n (%)
Female 70 (60)
Male 46 (40)
Education, n (%)
Primary/secondary school 19 (16)
Vocational education 72 (62)
Higher education 20 (18)
University 5 (4)
Occupation, n (%)
Working/studying 50 (43)
Not working/studying (including housework) 66 (57)
Axis I co-morbidity, n (%)
Yes 60 (52)
Anxiety disorder 53 (46)
Somatoform disorder 8 (7)
Substance use disorder 15 (13)
Other disorder 15 (13)
No 56 (48)
Mean duration of symptoms at start of study, months (S.D.) 7.7 (14.3)
Therapy, n (%)
CBT 44 (38)
IPT 40 (34)
CBT and antidepressant medication 17 (15)
IPT and antidepressant medication 15 (13)
Mean BDI score (S.D.)
Baseline 24.8 (9.1)
After 8 weeks 18.8 (10.1)
After 16 weeks 14.9 (9.8)
After 26 weeks 12.7 (10.0)
After 52 weeks 14.5 (11.9)
After 104 weeks 12.0 (10.7)
Mean SF-36 score (S.D.)
Baseline 8.7 (1.4)
After 8 weeks 9.5 (1.6)
After 16 weeks 10.2 (1.8)
After 26 weeks 10.5 (2.0)
After 52 weeks 10.3 (2.2)
After 104 weeks 10.6 (2.1)
Mean CAPE score (S.D.) 25.09 (6.0)
MDQ score
Mean part A (S.D.)a 5.1(3.5)
Part B, n (%)b
Not co-occurring 43 (49)
Yes co-occurring 66 (61)
Part C, n (%)c
No impact 47 (42)
Mild impact 44 (40)
Moderate impact 16 (14)
Severe impact 4 (4)
S.D., Standard deviation; CBT, cognitive behavioural theory; IPT, interpersonal
therapy; BDI, Beck Depression Inventory; SF, Short Form-36; CAPE, Community
Assessment of Psychic Experiences; MDQ, Mood Disorder Questionnaire.
a Part A addresses 13 yes/no questions addressing the occurrence of (hypo)manic
symptoms.
b Part B rates the co-occurrence of multiple symptoms (yes/no).
c Part C addresses the level of impact of these symptoms on the individual’s daily
life (none, mild, moderate, severe).
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No interactions were found for either CAPE score or
MDQ score with treatment groups predicting either
depression or functioning over time, nor was there
an interaction between CAPE score and MDQ score
predicting depression or functioning over time (all
p>0.05).
Subclinical psychotic experiences and bipolar
symptoms predicting depression and functioning
over time
Controlling for baseline depression (Table 3), CAPE
score signiﬁcantly predicted (i) depression score over
time (i.e. more subclinical psychotic experiences pre-
dicted more severe depression over time), (ii) non-
remission (i.e. more subclinical psychotic experiences
increased a patient’s probability of not reaching re-
mission) and (iii) relapse. CAPE score did not predict
time to remission or level of functioning. No inter-
action was found between CAPE score with time in
predicting BDI score (p=0.69). Controlling for baseline
depression, MDQ scores predicted an increased risk of
relapse, but MDQ did not signiﬁcantly predict any of
the other outcomes (depression or functioning).
Co-morbidity
Patients with more psychotic experiences reported
more co-morbidity compared with patients with
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Fig. 2. Bivariate plot of subclinical psychotic experiences (Community Assessment of Psychic Experiences; CAPE) and bipolar
symptoms (Mood Disorder Questionnaire; MDQ).
Table 2. Pearson’s bivariate and partial correlations of BDI with, respectively, CAPE and MDQ score at all time points
BDI score
Baseline 8 weeks 16 weeks 26 weeks 52 weeks 104 weeks
Bivariate correlations
CAPE 0.32*** 0.45*** 0.28** 0.24* 0.38** 0.35**
MDQ 0.32*** 0.28*** 0.12 0.07 −0.04 0.08
Partial correlations
CAPE 0.20* 0.38*** 0.27** 0.24* 0.42*** 0.37**
MDQ 0.20* 0.07 −0.04 −0.06 −0.23 −0.10
BDI, Beck Depression Inventory; SF, Short Form-36; CAPE, Community Assessment of Psychic Experiences; MDQ, Mood
Disorder Questionnaire.
*** p<0.0.001, ** p<0.01, * p<0.05.
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fewer psychotic experiences [χ2(1)=9.21, p=0.002].
However, repeating all analyses while controlling
for co-morbidity showed that the results did not
change (in effect size or in signiﬁcance), indicating
that co-morbidity was not a confounder in the associ-
ation between depression and subclinical psychosis.
Discussion
The present study showed that co-presence of subclini-
cal psychotic experiences and subclinical bipolar spec-
trum features is common in out-patients presenting for
treatment of MDD. It should be emphasized that these
individuals did not meet DSM-IV criteria for psychotic
depression or bipolar disorder. Nevertheless, subclini-
cal co-presence was clinically relevant, as psychotic
experiences were shown to have an impact on both
treatment outcome and course of MDD. Controlling
for baseline level of depression, co-presence of sub-
clinical psychotic experiences was associated with
higher levels of depression over time. Furthermore,
individuals who more often reported subclinical psy-
chotic experiences were more than seven times more
likely to not reach remission of their depressive symp-
toms, and had an almost four-fold higher probability
of relapse. Thus, subclinical psychotic experiences pre-
dicted poorer response to psychotherapeutic treatment
of depression. As reported earlier, no differences em-
erged between the different therapies (CBT and IPT),
either alone or in combination with pharmacotherapy
(Peeters et al. 2013). With the exception of the ﬁnding
that subclinical bipolar spectrum features predicted
relapse, no effects on course or outcome of MDD
were found for bipolar spectrum symptoms.
The elevated number of depressed subjects that
endorsed both subclinical psychotic experiences and
bipolar spectrum features in this sample as well as
the signiﬁcant correlation between these symptoms
dimensions are in line with earlier suggestions of con-
siderable overlap between these three constructs
(van Os & Kapur, 2009; Perlis et al. 2011). It was also
shown that the association between depressive and
bipolar symptoms was mediated by subclinical psy-
chotic experiences, as the partial correlation between
depression and bipolar symptoms was no longer sig-
niﬁcant after controlling for subclinical psychotic
experiences.
Our ﬁnding that subclinical psychotic experiences
have a negative impact on the clinical manifestation
of depression, both in terms of severity and of develop-
ment over time, concurs with earlier work in the
general population (Olfson et al. 2002; van Rossum
et al. 2011; Wigman et al. 2012) as well as in a clinical
sample (Perlis et al. 2011). In the latter, it was shown
that depressed individuals with psychotic experiences
responded less well to four consecutive pharmacologi-
cal interventions. Our results indicate that the same
applies to depressed patients when treated with
state-of-the-art evidence-based psychotherapy (CBT
or IPT), either alone or combined with pharmacother-
apy. These results are also consistent with data from
earlier studies into the outcomes of syndromal psycho-
tic depression showing more chronicity, higher risk of
recurrence, and lower levels of psychosocial function-
ing in comparison with non-psychotic depression
(Johnson et al. 1991; Coryell et al. 1996).
Several possible explanations for the negative impact
of psychotic experiences on treatment response in
MDD can be suggested. First, psychotic symptoms
have been shown to be indicators of psychopathologi-
cal severity (van Os et al. 1999; Hanssen et al. 2003; van
Rossum et al. 2011; Kelleher et al. 2012b). Therefore,
patients with psychotic experiences may be those that
present with more severe symptoms, expressed as
Table 3. CAPE and MDQ predicting depression and functioning over time while controlling for baseline depression/functioning
CAPE MDQ
B/OR/HR (95% CI) β p B/OR/HR (95% CI) β p
Depression B 6.47 (2.40–10.54) 0.20 0.002 B −0.01 (−0.43 to 0.40) −0.00 0.962
Functioninga B −0.47 (−1.21 to 0.27) −0.08 0.213 B −0.01 (−0.08 to 0.06) −0.02 0.813
Non-remission OR 7.51 (1.46–38.55) 0.016 OR 1.01 (0.88–1.16) 0.888
Relapse OR 3.85 (1.11–13.39) 0.034 OR 1.16 (1.01–1.33) 0.037
Time to remission HRb 0.72 (0.43–1.20) 0.203 HRb 1.18 (0.71–1.94) 0.521
CAPE, Community Assessment of Psychic Experiences; MDQ, Mood Disorder Questionnaire; B, unstandardized regression
coefﬁcient; OR, odds ratio; HR, hazard ratio; CI, conﬁdence interval; β, standardized regression coefﬁcient.
a Analysis on functioning was additionally controlled for treatment group.
b HR=increase in odds for remission over time with the increase of one point of the CAPE/MDQ score.
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‘co-morbidity’, since this was not an exclusion cri-
terion. Post hoc analyses showed that this was indeed
the case: patients with more psychotic experiences re-
ported more co-morbidity compared with patients
with fewer psychotic experiences [χ2(1)=9.21, p=
0.002]. However, repeating the analyses while con-
trolling for co-morbidity showed that the results did
not change (in effect sizes or in signiﬁcance), indicating
that co-morbidity was not a confounder in the associ-
ation between depression and subclinical psychosis.
Another mechanistic explanation to consider is that
individuals with psychotic experiences may have
higher levels of neurocognitive alterations and nega-
tive symptoms (Simons et al. 2007; Blanchard et al.
2010; Kelleher et al. 2012a). Alterations in these domains
may reduce the ability to engage in or to beneﬁt from
psychological therapies. It may be argued that, along
a dimensional scale, neurobiological, cognitive and
emotional processes may show progressively more
alterations with increasing vulnerability to or presence
of psychotic symptoms (Kaymaz & Van Os, 2009;
Stetler & Miller, 2011). For example, low self-esteem
and higher levels of depression are linked to paranoid
delusions that, through cognitive performance difﬁcult-
ies, may impede daily functioning, adequate problem
solving and, possibly, effectiveness of psychotherapy
(Chadwick et al. 2005; Bentall et al. 2009).
Subclinical bipolar spectrum features were more
weakly associated with treatment response in the
analyses. This ﬁnding is similar to the results reported
by Perlis et al. (2011), who also found that psychotic
rather than bipolar symptoms have a negative impact
on treatment response in MDD. Taken together, these
ﬁndings contradict the results from some other reports
and question the hypothesis that many individuals
with treatment-resistant MDD in fact have unrecog-
nized bipolar (spectrum) disorder (Manning, 2003;
Parker et al. 2005; Sharma et al. 2005; Smith et al.
2009; Dudek et al. 2010). One of the explanations of
these diverging results, as suggested by Perlis et al.
(2011), may be differences in the operationalization of
bipolar spectrum disorder, which sometimes includes
psychotic symptoms (Smith et al. 2009). However,
this does not apply to the comparison of results
between our and some earlier studies; elevated MDQ
scores were in all these studies used as proxy for the
presence of bipolar spectrum disorder. Second, differ-
ences in diagnostics between studies may explain
divergent results. In our study, SCID-I interviews
were used in the diagnostic procedure, which is a
more reliable diagnostic tool for the detection of bi-
polar disorder than a screening instrument such as
the MDQ (Zimmerman, 2012). Thus, patients meeting
criteria for bipolar disorder were excluded on the
basis of SCID-I-derived classiﬁcation before ﬁlling
out the MDQ. Third, the use of the MDQ, which was
originally developed as a screening instrument, as a
diagnostic tool to assess bipolar spectrum features,
as some studies have done, is questionable and
probably will result in many false-positive cases
(Zimmerman, 2012). Patients screening false positive
on the MDQ appear to present with a broad variety
of co-morbid Axis I and II disorders, more severe
depressive symptoms and suicidality, which are
known to impede the effectiveness of standard treat-
ments for MDD (van den Berg et al. 2010; Zim-
merman et al. 2010a,b). Although many patients in
the treatment programme present with co-morbid dis-
orders, the diagnostic procedure excluded subjects
whose co-morbid symptomatology, such as borderline
personality disorder, dominated the clinical presen-
tation. This type of undetected co-morbidity in other
studies may explain the proposed association between
‘subclinical bipolar spectrum features’ and worse treat-
ment outcome.
Taken together, the ﬁndings that (i) the correlation
between MDD and bipolar symptoms is reducible in
part to subclinical psychotic experiences and (ii) sub-
clinical psychotic experiences but not bipolar symp-
toms make an impact on the course and outcome of
MDD suggest that subclinical psychosis is of greater
importance with regard to MDD than bipolar spec-
trum features. Although the association between MDD
and psychosis was shown to be more prominent, sub-
clinical psychotic experiences and bipolar spectrum
features were still correlated, even when controlling
for depressive symptoms. Thus, overlap exists between
these different domains.
The results are in line with earlier work that has
hypothesized that depression, psychosis, and, perhaps
to a lesser extent, mania share underlying vulner-
abilities (van Os & Kapur, 2009). Assuming that affec-
tive and psychotic disorders are on an aetiological and
phenomenological continuum (van Rossum et al. 2011),
this would suggest that individuals who are vulner-
able with respect to one dimension are also more
prone to express the other (Hanssen et al. 2003). This
is supported by high levels of affective dysregulation
in clinical psychosis (e.g. Buckley et al. 2009) and,
vice versa, frequent reports of psychotic symptoms in
affective disorders (Hanssen, et al. 2003; Varghese
et al. 2011; Wigman et al. 2012). Considerable overlap
in symptom expression is one of the most important
arguments that categorical models may not adequately
describe psychopathology as it exists in nature
(Kendell & Jablensky, 2003). A dimensional model,
delineating psychopathology not as a binary phenom-
enon, but along a continuous scale of severity, may
complement the traditional categorical approach
(Allardyce et al. 2007; Kendler et al. 2011).
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The current results have clinical implications, as it is
suggested that treatment of psychosis in non-psychotic
disorders is essential (van Os & Murray, 2013).
Clinicians should be aware of, and routinely enquire
about, psychotic experiences, even when below the
clinical severity threshold. In addition, patients should
be informed that these phenomena are commonly pre-
sent in the context of depression and may have a nega-
tive impact on course and outcome. Research has
shown that psycho-education or simply discussing psy-
chotic experiences reduces their stressful effects (van
der Gaag et al. 2012), which in turn may be beneﬁcial
for recovery. Electroconvulsive therapy or antipsychotic
medication may need to be considered or, alternatively,
cognitive behavioural therapy or other psychother-
apeutic approaches may be indicated. Future work is
required to formally assess the effects of these.
The results of the current study should be inter-
preted in the light of its strengths and limitations.
First, the CAPE refers to lifetime experiences and
results do not necessarily reﬂect current symptoma-
tology. Therefore, it could be argued that the effect of
subclinical psychotic symptoms may not be caused
by current co-presence of such symptoms. Neverthe-
less, work in this area has shown that even when
assessing lifetime experience of psychotic symptoms,
a positive response most often refers to a recent experi-
ence (Kelleher et al. 2012). Psychotic experiences as
listed in the CAPE have a low reporting threshold in
general as well as in clinical populations. We therefore
analysed the sum score in order to assess linear effects
across the entire distribution of severity. In addition,
dichotomized CAPE scores, indexing a threshold
measure of psychosis, were used in the survival analy-
sis, yielding identical results. A second limitation that
is inherent to longitudinal studies, especially involving
clinical samples, is attrition. This may have led to an
underestimation of effects and especially of the preva-
lence of relapse. However, the use of a data set in long
format partly offsets this problem by preventing list-
wise deletion of participants and thus ensuring in-
clusion of the maximum amount of data. Also, patients
who dropped out only differed in age from patients
who completed the study. The fact that patients were
not randomly assigned to a treatment condition
could be seen as a drawback in the study design. How-
ever, this is in fact an important strength of the study,
examining the effectiveness of empirically supported
treatments for MDD as it is delivered in daily practice
to patients who actively seek help and choose their
preferred treatment, which has been hypothesized to
enhance outcome (Peeters et al. 2012). Furthermore,
individuals who choose different treatment options
did not differ on baseline BDI score, CAPE score or
MDQ scores, suggesting that there was no possibility
of bias related to treatment choice based on level of
psychotic of bipolar subclinical symptoms. Another -
important strength of the current study is that a
structured diagnostic interview ensured accurate clas-
siﬁcation of patients’ symptoms, and well-deﬁned, well-
administered therapeutic approaches were assessed
with a psychometrically robust outcome measure.
Therefore, the results can be interpreted as truly reﬂect-
ing the effect of subclinical psychotic experiences on
the effectiveness of psychotherapy, alone or in combi-
nation with antidepressants, in routine clinical practice.
However, no formal assessment of Axis II diagnoses
were carried out in the current study, with the excep-
tion of a small group of patients where a strong clinical
impression existed of personality problems requiring
further assessment. Patients so diagnosed with signiﬁ-
cant Axis II pathology were referred to a specialized
treatment setting and would not have been included
in the current analyses. Thus, for most patients, psy-
chopathology ratings were made as required for
SCID-I diagnoses only.
A ﬁnal limitation is that the current study did not
investigate the potential impact of other factors associ-
ated with the course of both psychosis and depression,
such as trauma (Kessler et al. 2010; Varese et al. 2012) or
cannabis use (Degenhardt et al. 2003; Semple et al.
2005). Environmental risks associated with psychosis
may mediate the observed associations and should
be addressed in future research. Dimensional ap-
proaches to psychopathology and the use of a categ-
orical system of discrete clinical diagnoses are not
necessarily mutually exclusive: both can be used to
construct a threshold mode of disease (Kendell &
Jablensky, 2003), and help building staging and proﬁ-
ling models that can guide clinical decision making
(Hetrick et al. 2008; McGorry & van Os, 2013). Future
studies will have to show whether the presence of life-
time or current psychotic experiences warrant modiﬁ-
cation of standard antidepressant treatments such as
the addition of cognitive skills training or metacogni-
tive training to psychotherapeutic approaches (Singer
& Dobson, 2007; Barahmand et al. 2008; Moritz et al.
2011) and the addition of antipsychotics to antidepress-
ants (Farahani & Correll, 2012).
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